Summary
The provided label excerpts only address contraindications and fetal toxicity/pregnancy discontinuation. The AI-generated claims provided (pharmacokinetics, clearance timing, drug testing, and urgent symptom guidance) are not supported or contradicted by the supplied label text, and several material label domains are therefore not verifiable from the provided prescribing information.
Category Scores
Accurate Statements
Discontinuation of lisinopril and hydrochlorothiazide tablets should occur as soon as pregnancy is detected due to fetal toxicity risk.
Boxed Warning (Fetal Toxicity): “When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide tablets as soon as possible.”; Warnings: Fetal Toxicity: same instruction; Use in Pregnancy (Section 8): same instruction.
Unsupported Statements
Lisinopril is eliminated largely unchanged by the kidneys.
No pharmacokinetic/elimination wording was provided in the supplied prescribing information excerpts.
Lisinopril’s elimination half-life is about 12 hours.
No half-life information was provided in the supplied prescribing information excerpts.
With repeated dosing, lisinopril active drug levels steady out in a few days.
No steady-state timing information was provided in the supplied prescribing information excerpts.
With first-order elimination, it typically takes about 4 to 5 half-lives for most of the drug to clear from the bloodstream.
No general clearance-by-half-life statements were provided in the supplied prescribing information excerpts.
With typical kidney function, the time for most of lisinopril to clear from the bloodstream is roughly 2 to 3 days.
No kidney-function-specific clearance-time information was provided in the supplied prescribing information excerpts.
Because lisinopril is cleared by the kidneys, reduced kidney function can prolong how long it stays in the body.
No renal impairment pharmacokinetic/clearance prolongation statements were provided in the supplied prescribing information excerpts.
People with impaired renal function may need dose adjustments.
No dosing-in-renal-impairment guidance was provided in the supplied prescribing information excerpts.
Lisinopril blood-pressure effects usually fade over about 1 to 2 days after the last dose.
No duration of blood-pressure effect/de-recruitment timing was provided in the supplied prescribing information excerpts.
Blood-pressure effects track drug exposure as medication levels decline.
No exposure-effect relationship statements were provided in the supplied prescribing information excerpts.
Standard drug-of-abuse urine tests usually target drugs like opioids, cocaine, and THC rather than blood-pressure medicines.
No statements about drug-of-abuse testing panels or lisinopril detectability were provided in the supplied prescribing information excerpts.
Drug-test detection of lisinopril depends on the specific test type and cutoff used by the lab.
No statements about detection, test type, or cutoff values were provided in the supplied prescribing information excerpts.
Seek medical advice urgently if taking lisinopril and developing swelling of the face or lips, which is possible angioedema.
No symptom-triggered urgent-action counseling (e.g., angioedema presentation) was provided in the supplied prescribing information excerpts.
Seek medical advice urgently if taking lisinopril and developing fainting or severe dizziness.
No symptom-triggered urgent-action counseling (e.g., syncope/severe dizziness) was provided in the supplied prescribing information excerpts.
Seek medical advice urgently if taking lisinopril and developing symptoms of very low blood pressure.
No symptom-triggered urgent-action counseling (e.g., hypotension presentation) was provided in the supplied prescribing information excerpts.
Seek medical advice urgently if taking lisinopril and developing signs of kidney problems such as decreased urination and major lab abnormalities.
No symptom-triggered urgent-action counseling (e.g., oliguria/major lab abnormalities) was provided in the supplied prescribing information excerpts.
Contradictions
Important Omissions
Label-supported pharmacokinetic, half-life, clearance timing, renal impairment dosing/PK guidance, and blood-pressure effect duration are not present in the provided label excerpts, preventing validation of those claims.
Importance:
Moderate
Label-supported guidance for specific adverse-event symptoms (angioedema, hypotension, renal impairment presentations) is not present in the provided label excerpts, preventing validation of urgent-advice counseling claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Pregnancy-discontinuation guidance matches the supplied boxed warning and warnings text. However, multiple other clinically relevant claims (pharmacokinetic timing, renal impairment dose adjustments, and urgent symptom escalation) are unsupported by the provided prescribing information excerpts; if incorrect, they could mislead patients/clinicians.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most non-pregnancy claims are not supported by the supplied FDA label excerpts; only pregnancy/discontinuation language is verifiably aligned.
Suggested Improvement
Limit statements to content explicitly present in the provided prescribing information excerpts (e.g., boxed warning/pregnancy discontinuation). Remove or qualify pharmacokinetic, renal dosing adjustment, drug testing, and urgent symptom guidance unless corresponding label sections are provided.